ESC 2020 Prof. Verheugt briefly discusses the findings of the ATPCI trial, which evaluated the effect of trimetazidine compared to placebo in patients who underwent PCI.
ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.
ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.
ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.
ESC 2020 Ticagrelor monotherapy after 3 months DAPT reduced risk of bleeding without increasing rate of thrombotic events compared to ticagrelor plus aspirin in high risk CDK patients undergoing PCI.
ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.
ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.
ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.
ESC 2020 Although networking opportunities are poor during this year's ESC congress, there are plusses for a digital congress. Prof. Casadei lists some of them.
ESC 2020 Ertugliflozin reduced time to first HF hospitalization, total HF hospitalizations and total HF hospitalizations/CV death events in T2DM patients with ASCVD.
ESC 2020 Using data of the UK Biobank, this study showed that BMI and a polygenic score for diabetes have independent and additive effect on lifetime risk of diabetes, and should be used in combination for risk prediction.
ESC 2020 Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of the anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.